Digital health company developing autonomous AI software that analyzes retinal fundus images to screen for diabetic retinopathy and other conditions
Digital health company developing autonomous AI software that analyzes retinal fundus images to screen for diabetic retinopathy and other conditions. Its FDA-cleared AEYE-DS enables rapid, point-of-care screening using portable or tabletop cameras, with instant results and no physician interpretation required; AEYE-X is intended to screen for a broader range of diseases from retinal images.